This post first appeared on SEC Filings – Market Exclusive

ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV) Files An 8-K Other Events
Item 8.01 Other Events.

On June 12, 2019 the Registrant completed its new marketing plan with sales projections. A copy of that plan is an Exhibit to this report.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements

None

(b) Exhibits

99.1 Marketing Plan with sales projections


ENDONOVO THERAPEUTICS, INC. Exhibit

To view the full exhibit click here

About ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV)

Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.

The post ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV) Files An 8-K Other Events appeared first on Market Exclusive.

--
Copyright in text and images in this article belong to the original source.

This post first appeared on SEC Filings – Market Exclusive